In this sense, GARP‐overexpressing MSCs could be advantageous for the treatment of inflammatory/autoimmune diseases as the GARP/TGF‐β axis promotes immune tolerance, in part, through the induction of Tregs.81 However, GARP/TGF‐β was recently shown to promote the osteogenic differentiation of MSCs in vitro.82 Thus, GARP++MSCs could be ideal for bone regeneration applications while giving rise to unwanted differentiation when used in inflammatory/autoimmune diseases. The gene discussed is TGFB1; the disease is autoimmune disease.